Dr. Bassam Damaj, President and CEO of Innovus Pharmaceuticals, Inc. (INNV), Interviews with The Wall Street Transcript
67 WALL STREET, New York - April 26, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation
Companies include: Innovus Pharmaceuticals, Inc. (INNV) and many more.
In the following excerpt from the Biotechnology and Pharmaceuticals Report, the President and CEO of Innovus Pharmaceuticals, Inc. (INNV) discusses company strategy and the outlook for this vital industry:
TWST: Please provide an overview of Innovus Pharmaceuticals and its operations.
Dr. Damaj: Innovus Pharmaceuticals is headquartered in La Jolla, California. We're a small, emerging pharmaceutical company and what we do specifically is we deliver innovative and uniquely presented and packaged health care solutions to patients in specific therapeutic areas, such as inflammation and pain, sexual dysfunction, cough and cold, and respiratory diseases. We operate in the prescription and consumer health space. I came on board on January 22 with a plan, and we put in place a three-stage growth plan for the company toward our main goal of listing the company on the Nasdaq stock exchange in 2014.
The first step in our business plan was to secure the right commercial assets, and we are able to build a robust pipeline for our APEAZ line of products, which includes APEAZ for arthritis pain, APEAZ acne pads, APEAZ hemorrhoids cream and APEAZ Zinc for cold and cough. In addition, we acquired the ex-U.S. rights to CIRCUMSerum to increase sensitivity to the penis and brought in a premature ejaculation product called EjectDelay.
The second step was to secure the financing of the company, and this is was done by an investment I did in the company that secured us until Q1 2014. This was a great accomplishment, not just because the company now has financing, but also because the auditors removed the liquidity going concern from our financials. It was a huge accomplishment for the company, especially for our market cap.
Finally, the third step in our business plan is to start the launch and the commercial stage, which will bring revenues into the company. This is the step that we are currently working diligently on achieving. And all these three steps actually do follow toward our one main goal, of listing the company on Nasdaq in 2014...
For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
